STING1 and neoplasm: Presently, STING agonists are undergoing evaluation in conjunction with immune checkpoint blockade (ICB) to exploit STING signaling for activating anti-tumor responses, with some demonstrating efficacy and a manageable safety profile (NCT03010176) [447].